Mereo BioPharma grants new options to CSO Lewicki

Mereo BioPharma Group plc granted new share options to Chief Scientific Officer John A. Lewicki on February 1, 2026.

Rhea-AI Filing Summary

Mereo BioPharma Group plc granted new share options to Chief Scientific Officer John A. Lewicki on February 1, 2026. The awards cover 139,913 share options with a $0.44 exercise price, 46,637 share options with a $1.00 exercise price, and 145,000 share options with a $0.44 exercise price, all over American Depositary Shares.

For the 139,913 options, 25% of the underlying shares vest on February 1, 2027, with the rest vesting in equal monthly installments over the following three years. The 145,000 options vest in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.

Insider Trade Summary

Grant/Award: 331,550 shares

Grant/Award 3 txns

Insider Lewicki John A.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Options (Right to buy)	139,913	$0.00	$0.00
Grant/Award	Share Options (Right to buy)	46,637	$0.00	$0.00
Grant/Award	Share Options (Right to buy)	145,000	$0.00	$0.00

Holdings After Transaction: Share Options (Right to buy) — 331,550 contracts (Direct)

Footnotes (3)

1. F1. 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.
2. F2. Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
3. F3. Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mereo BioPharma (MREO) disclose in this Form 4 filing?

Mereo BioPharma disclosed new share option grants to Chief Scientific Officer John A. Lewicki on February 1, 2026. These derivative awards cover American Depositary Shares with specified exercise prices and vesting schedules, documenting updated derivative holdings directly beneficially owned.

How many share options were granted to John A. Lewicki at Mereo BioPharma?

John A. Lewicki received three option grants: 139,913 options at a $0.44 exercise price, 46,637 options at a $1.00 exercise price, and 145,000 options at a $0.44 exercise price. All relate to American Depositary Shares of Mereo BioPharma Group plc.

What are the vesting terms of the 139,913 Mereo BioPharma share options?

For the 139,913 share options, 25% of the underlying shares vest and become exercisable on February 1, 2027. The remaining 75% then vest in equal monthly installments over the subsequent three years, creating a multi‑year, tenure-based vesting structure.

How do the 145,000 Mereo BioPharma share options vest?

The 145,000 share options vest in substantially equal monthly installments over one year from the February 1, 2026 grant date. This schedule provides full vesting after approximately one year, contingent on continued service during the monthly vesting periods.

What does each Mereo BioPharma American Depositary Share represent?

Each Mereo BioPharma American Depositary Share (ADS) represents five ordinary shares of the issuer. The ordinary shares have a nominal value of GBP 0.003 per share, so the options over ADS indirectly relate to a larger number of underlying ordinary shares.

Is John A. Lewicki a director or officer of Mereo BioPharma?

John A. Lewicki is reported as an officer of Mereo BioPharma Group plc, serving as Chief Scientific Officer. He is not identified in this filing as a director or a 10% owner, and the options are reported as directly owned derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lewicki John A.

(Last) (First) (Middle)

C/O MEREO BIOPHARMA GROUP PLC

4TH FLOOR, ONE CAVENDISH PLACE

(Street)

LONDON X0 W1G 0QF

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mereo BioPharma Group plc [ MREO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Options (Right to buy)	$0.44	02/01/2026		A		139,913		(1)	02/01/2036	American Depositary Shares(2)	139,913	$0.00	139,913	D
Share Options (Right to buy)	$1	02/01/2026		A		46,637		(1)	02/01/2036	American Depository Shares(2)	46,637	$0.00	46,637	D
Share Options (Right to buy)	$0.44	02/01/2026		A		145,000		(3)	02/01/2036	American Depository Shares(2)	145,000	$0.00	145,000	D

Explanation of Responses:

1. 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

2. Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

3. Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.

	/s/ Christine Fox, by power of attorney	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.